{"id":"NCT02600923","sponsor":"Pfizer","briefTitle":"Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate","officialTitle":"STUDY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE AS TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER FOR WHOM LETROZOLE THERAPY IS DEEMED APPROPRIATE","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-15","primaryCompletion":"2019-05-28","completion":"2019-05-28","firstPosted":"2015-11-09","resultsPosted":"2020-05-21","lastUpdate":"2022-01-20"},"enrollment":131,"design":{"allocation":"NA","model":null,"masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Advanced Breast Cancer Female"],"interventions":[{"type":"DRUG","name":"Palbociclib","otherNames":["Ibrance"]},{"type":"DRUG","name":"Letrozole","otherNames":["Femara"]}],"arms":[{"label":"Palbociclib + Letrozole","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to provide access to palbociclib in Mexico and in selected Latin American countries before it becomes commercially available to patients with HR positive/HER2-negative ABC who are appropriate candidates for letrozole therapy.","primaryOutcome":{"measure":"Number of Participants With All-causality Treatment-emergent Adverse Events (TEAEs)","timeFrame":"3 years","effectByArm":[{"arm":"Palbociclib+Letrozole","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":11},"locations":{"siteCount":24,"countries":["Argentina","Brazil","Colombia","Mexico"]},"refs":{"pmids":["37594640"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=A5481053"]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":130},"commonTop":["Neutropenia","Leukopenia","Anaemia","Neutrophil count decreased","Thrombocytopenia"]}}